日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comment on "Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study"

对“利用多组学分析可成药基因以促进阿尔茨海默病治疗:一项多队列机器学习研究”的评论

Xue, Jihao; Chen, Yitian; Chen, Ligang; Yin, Qijia

Commentary: Disulfidptosis-related gene signatures as prognostic biomarkers and predictors of immunotherapy response in HNSCC

评论:二硫键凋亡相关基因特征作为头颈部鳞状细胞癌的预后生物标志物和免疫治疗反应预测因子

Xue, Jihao; Xue, Cheng; Yin, Qijia; Chen, Ligang; Wang, Ming

Limitations of nomogram models in predicting survival outcomes for glioma patients

列线图模型在预测胶质瘤患者生存结果方面的局限性

Xue, Jihao; Liu, Hang; Jiang, Lu; Yin, Qijia; Chen, Ligang; Wang, Ming

Comprehensive analysis of palmitoylation-related proteins for prognostic risk evaluation and tumor immune microenvironment assessment in glioma.

对胶质瘤中棕榈酰化相关蛋白进行综合分析,以评估其预后风险和肿瘤免疫微环境。

Xue Jihao, Lin Li, Liu Chang, Yin Qijia, Wang Tao, Lai Rui, Chen Ligang, Yin Yiran, Wang Ming, Zhou Jie

Commentary: Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma

评论:TREM1的分子和免疫学特征及其作为胶质瘤预后指标的出现

Xue, Jihao; Luo, Zhilin; Wang, Tao; Yin, Qijia; Chen, Ligang

Limitations of applying the COX proportional hazards model to glioma studies

将COX比例风险模型应用于胶质瘤研究的局限性

Xue, Jihao; Chen, Yitian; Xue, Cheng; Yin, Qijia; Lai, Rui; Chen, Ligang; Wang, Ming

Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification

评论:磷酸化蛋白样蛋白3是胶质瘤中一种新型的预后和肿瘤免疫学标志物:一项多组学分析及实验验证

Xue, Jihao; Yin, Qijia; Wang, Ming; Li, Yanling